The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy.
Chaitra UjjaniAnthony MatoBrian T HillJohn N AllanFrederick LansiganRyan JacobsAlan SkarbnikHande TuncerJohn PagelDanielle BranderBruce D ChesonPaul BarrLindsey E RoekerJeffrey J PuNirav N ShahAndre H GoyStephen J SchusterNicole LamannaAlison SehgalConstantine S TamMazyar ShadmanPublished in: Blood and lymphatic cancer : targets and therapy (2020)
These data suggest greater intolerance, and possibly mortality, with ibrutinib in an older population. Patients should be educated regarding the potential complications related to ibrutinib and symptoms of concern to report.
Keyphrases
- chronic lymphocytic leukemia
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- cardiovascular events
- electronic health record
- type diabetes
- mesenchymal stem cells
- patient reported outcomes
- big data
- machine learning
- middle aged
- coronary artery disease
- sleep quality
- risk assessment
- cell therapy
- patient reported